ERR and exercise biology
Lab research
Animal research on an orally active chemical probe.2
MetabolicSmall molecule
SLU-PP-915
Chemically distinct, orally active pan-ERR agonist
Preclinical research chemical; no verified human therapeutic formulation.
What does it do?
Amino-acid sequence
Not applicable: this compound is not a single peptide.
Reference identity · not independently confirmed9
LengthNot a peptide sequence
Molecular weight · Da341.16 Da
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life18 min – 28 min8
Route / formulationSource page: Oral. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%–64%of reference level
Illustrative scenario using an unverified reference estimate. Shading shows the reported half-life range. No midpoint is assumed.
About 3% remaining after 1.5 h–2.33 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Billon C et al. JPET 2025/2026. PMID 41421047. DOI 10.1016/j.jpet.2025.103787.
Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Oral activity is an animal finding
Mouse experiments found improved treadmill distance and duration after oral administration adjusted for exposure. No human dose or benefit follows from those results.2
Doses & schedules
No verified human protocol or quantified community report included.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Oral
- Use period
- NOT ESTABLISHED - no human data
- Break
- UNKNOWN
Reported timing
Awaiting clinical trials
Animal and cell protocols 1
Laboratory exposures cannot establish a human dose.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| Oral | Exact dose for SLU-PP-915 not yet published; SLU-PP-332 reference: 50 mg/kg twice daily (IP) in mice | Study-dependent (animal studies only) | PRECLINICAL REFERENCE ONLY - rodent metabolic study (mouse)Reference report | Not specified | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. SLU-PP-332 and SLU-PP-915 are distinct small molecules. Source combination labels remain theoretical. Source route wording Oral gavage or IP injection (mice only) Source tabs Oral | |||||
| OtherIntraperitoneal | Exact dose for SLU-PP-915 not yet published; SLU-PP-332 reference: 50 mg/kg twice daily (IP) in mice | Study-dependent (animal studies only) | PRECLINICAL REFERENCE ONLY - rodent metabolic study (mouse)Reference report | Not specified | 9 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. SLU-PP-332 and SLU-PP-915 are distinct small molecules. Source combination labels remain theoretical. Source route wording Oral gavage or IP injection (mice only) Source tabs Oral | |||||
No protocols match these filters.
Side effects & safety
Human safety is unresolved
The checked material does not establish a human adverse-event rate or safe self-use regimen for this exact product.
3Unknown safety
Human PK, efficacy, reproductive effects and chronic safety unestablished.
Urgent
Cardiovascular symptoms, hypoglycemic confusion/sweating/fainting, jaundice, dark urine, abdominal pain or allergy.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
8 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
SLU-PP-332
Caution reportedRedundant ERR targeting.9
Reference report · Pep-Pedia label: Monitor CombinationRetatrutide
Caution reportedNo combination studies.9
Reference report · Pep-Pedia label: Monitor CombinationGLP-1 agonists
Caution reportedIncludes semaglutide/tirzepatide; untested.9
Reference report · Pep-Pedia label: Monitor CombinationMOTS-c
Unverified pairingUnproven mitochondrial pairing.9
Reference report · Pep-Pedia label: SynergisticAICAR
Unverified pairingUnproven exercise-mimetic pairing.9
Reference report · Pep-Pedia label: SynergisticNAD+
Unverified pairingUntested pairing.9
Reference report · Pep-Pedia label: Compatible5-Amino-1MQ
Unverified pairingUntested pairing.9
Reference report · Pep-Pedia label: CompatibleOther medicines and research compounds
Not establishedNo clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No universal bacteriostatic-water volume or validated preparation method is established for this entry.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Oral
The source explicitly limits handling to laboratory research and supplies no human protocol.
- Reported parameters
- It refers to study-specific DMSO/cosolvent vehicles or lipid-based rodent gavage formulations.
Its generic ERR-agonist solvent discussion is not a validated SLU-PP-915 preparation.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported concernProducts marketed for human consumptionReported variationResearch chemical - no human trial dataReported variationNo GMP standard existsReported appearanceLegitimate research supplier with COAReported concernInsoluble in water alone
9Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.9
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Research-market product identity, purity and formulation cannot be established from a publication.2
2 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
PreclinicalSource context
SLU-PP-332 and SLU-PP-915 are distinct small molecules. Source combination labels remain theoretical.
Compound identity & other names
An experimental ERR agonist studied in cells and mice. Oral activity in animals does not establish a human formulation, half-life or exercise benefit.
Preclinical research chemical; no verified human therapeutic formulation.
Chemically distinct, orally active pan-ERR agonist39
Pep-Pedia identity record
· 341.16 Da
Reference description; checked chemical identity takes precedence when available.9
How it may work
Pan-ERR activation changes mitochondrial and oxidative-metabolism gene expression.9
Oral activity is an animal finding
Mouse experiments found improved treadmill distance and duration after oral administration adjusted for exposure. No human dose or benefit follows from those results.
2Research areas and evidence gaps
ERR and exercise biology. Animal research on an orally active chemical probe.2
- Research-market product identity, purity and formulation cannot be established from a publication.
Additional uses listed by Pep-Pedia
Metabolic. Mitochondrial biogenesis, fat oxidation and exercise-like transcription.9
Performance. Rodent endurance research; no proven human benefit.9
Community reports Unvalidated
Pep-Pedia describes community interest and schedules; these are secondary reports, not measured clinical outcomes.3
Pep-Pedia does not establish a human dose; its quantitative schedules are explicitly animal research references.
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- "SLU-PP-915" 2026 2025 site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 5 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 7 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Source & limitations
The source displays “12 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1SLU-PP-915 Oral Exercise Mimetic - JPET 2025 (Billon et al.)Primary source checked
AI-PREPARED SUMMARY
Published online December 2025, January 2026 issue. Oral and intraperitoneal mouse experiments found exercise-related responses; the compound is chemically distinct from SLU-PP-332.
Pep-Pedia bibliography · Checked 2026-10-12
2Orally active SLU-PP-915 enhances aerobic exercise capacityPrimary source checked
AI-PREPARED SUMMARY
Published online December 2025, January 2026 issue. Oral and intraperitoneal mouse experiments found exercise-related responses; the compound is chemically distinct from SLU-PP-332.
Oral activity is an animal finding
Mouse experiments found improved treadmill distance and duration after oral administration adjusted for exposure. No human dose or benefit follows from those results.
Additional research · Checked 2026-10-12
3Pep-Pedia: SLU-PP-915 — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
4Discovery Chemistry: SLU-PP-915 Identified as Pan-ERR Agonist - Eur J Med Chem 2023 (Hampton et al.)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Cell assays showed similar potency across ERR isoforms and longer microsomal stability than SLU-PP-332; microsomal persistence is not a human half-life.
Reported population / model
Medicinal chemistry
Reported study details
ERR transactivation reporter assays · In vitro metabolic stability · HLM · European Journal of Medicinal Chemistry 258: 115582, Oct 2023
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Novel Pan-ERR Agonists in Heart Failure - Circulation 2024 (Xu, Billon et al.)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Both compounds improved mouse pressure-overload heart failure; SLU-PP-915 acted earlier, with metabolic changes rather than a substantial rise in mitochondrial mass.
Reported population / model
TAC heart failure model (mice)
Reported study details
Both SLU-PP-332 and SLU-PP-915 tested · 25 mg/kg BID IP x ~6 weeks · Circulation 149(3): 227-250, Jan 2024
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Synthetic ERRα/β/γ Agonist Induces Aerobic Exercise Response - ACS Chemical Biology 2023 (Billon et al.)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: SLU-PP-332 increased mouse running time and distance through ERRα-dependent mechanisms; the experiment did not establish SLU-PP-915 performance effects.
Reported population / model
Multiple mouse models
Reported study details
SLU-PP-332 · 50 mg/kg IP BID x 7-15 days · Treadmill, skeletal muscle fiber analysis, RNA-seq · 20 authors including Evans (Salk Institute)
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Pan-ERR Agonist Alleviates Metabolic Syndrome - JPET 2024 (Billon et al.)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The weight/metabolic experiments tested SLU-PP-332, not SLU-PP-915; shared receptor activity does not establish identical efficacy.
Reported population / model
Diet-induced obese (DIO) and ob/ob mice
Reported study details
SLU-PP-332 · 50 mg/kg IP BID x 28 days · Comprehensive metabolic assessment
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Pep-Pedia: SLU-PP-915 — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 18 min – 28 min and a peak time of 30 min. Stated attribution: Billon C et al. JPET 2025/2026. PMID 41421047. DOI 10.1016/j.jpet.2025.103787.. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
9Pep-Pedia: SLU-PP-915 — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12